초록 열기/닫기 버튼
Purpose: To evaluate the effect of different doses of intravitreal triamcinolone acetonide on diffuse diabetic macular edema. Methods: In a retrospective study, 44 eyes with diffuse diabetic macular edema were treated with an intravitreal injection of 4 ㎎ (n=12 eyes), 8 ㎎ (n=17) or 25 ㎎ (n=15) of triamcinolone acetonide (TA). Optical coherence tomography, best-corrected logMAR visual acuity and Goldmann tonometry were performed at baseline, 1 week, and 1, 3, 6, 9 and 12 months after treatment. Mean follow-up was 9.8 months (standard deviation=2.3) with a range of 5-12 months. Results: The duration of intravitreal TA effects on macular thickness and visual acuity increased with increasing dosage. An observed increase in intraocular pressure induced by TA was not significantly associated with dosage. Conclusions: In patients with diffuse diabetic macular edema who receive intravitreal TA, effects may last longer after a dosage of 25 ㎎, than after lower doses of 8 ㎎ or 4 ㎎.
Purpose: To evaluate the effect of different doses of intravitreal triamcinolone acetonide on diffuse diabetic macular edema. Methods: In a retrospective study, 44 eyes with diffuse diabetic macular edema were treated with an intravitreal injection of 4 ㎎ (n=12 eyes), 8 ㎎ (n=17) or 25 ㎎ (n=15) of triamcinolone acetonide (TA). Optical coherence tomography, best-corrected logMAR visual acuity and Goldmann tonometry were performed at baseline, 1 week, and 1, 3, 6, 9 and 12 months after treatment. Mean follow-up was 9.8 months (standard deviation=2.3) with a range of 5-12 months. Results: The duration of intravitreal TA effects on macular thickness and visual acuity increased with increasing dosage. An observed increase in intraocular pressure induced by TA was not significantly associated with dosage. Conclusions: In patients with diffuse diabetic macular edema who receive intravitreal TA, effects may last longer after a dosage of 25 ㎎, than after lower doses of 8 ㎎ or 4 ㎎.
